Getinge (PINK:GETI B) subsidiary Atrium Medical said today that it agreed to deal its biosurgery business to the parent company of SeCQure Surgical for an undisclosed amount. Göteborg, Sweden-based Getinge acquired the biosurgery unit, which makes soft tissue reinforcement devices, in the $680 million deal for Atrium back in 2011. Today Getinge said it agreed to sell the business, which […]
Atrium Medical Corp.
The National Venture Capital Assn. is spearheading a drive to get a bill through the U.S. Senate that would make it easier for small companies to raise money by going public.
The "IPO On Ramp" measure would ease the regulatory requirements for IPOs and temporarily reduce the reporting burdens imposed by the Sarbanes-Oxley Act.
Johnson & Johnson’s (NYSE:JNJ) Ethicon Endo-Surgery division finished its acquisition of Minnesota-based medical device reprocessor SterilMed Inc for an undisclosed amount.
SterilMed reprocesses medical devices and provides equipment repair and pre-owned equipment sales services. Johnson & Johnson said it plans to keep the SterilMed brand running as it integrates the business into the EES segment.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Sweden-based Getinge Group announced a definitive agreement to acquire soft tissue reinforcement technology developer Atrium Medical for $680 million.
Atrium will operate as an independent, self-contained unit of Getinge subsidiary Maquet Cardiovascular and will continue to be led by current Atrium president, Trevor Carlton, according to a press release.
— Atrium’s products strategically augment MAQUET Cardiovascular’s global business —
WAYNE, N.J., Oct. 3, 2011 /PRNewswire/ — GETINGE GROUP (STO:GETIB) and its subsidiary, MAQUET Cardiovascular, a global leading provider of cardiovascular technologies, announced today that it has signed a definitive agreement to acquire Atrium Medical Corporation for $680 million. Atrium is a leader in medical device technologies for interventional cardiology and radiology, chest trauma care and thoracic drainage, vascular surgery, and general surgery. Atrium will operate as an independent, self-contained business unit of MAQUET Cardiovascular and will be led by current Atrium president, Trevor Carlton.
C.R. Bard Inc.’s (NYSE:BCR) peripheral vascular unit sued a pair of competitors over a patent covering its prosthetic vascular grafts made from expanded polytetrafluoroethylene.
The lawsuit, filed in the U.S. District Court for Arizona, accuses Endologix Inc. (NSDQ:ELGX) and Atrium Medical Corp. of infringing Bard’s patent for "Prosthetic Vascular Graft." Bard alleges that Atrium’s Advanta line of grafts and stents, its iVena vascular patch and Flixene graft violate the patent and that Endologix runs afoul with its Powerlink stent grafts.
Atrium Medical Corp. entered into two three-year deals with Charlotte, N.C.-based group purchasing organization Premier Inc.
Premier awarded the Hudson, N.H.-based soft tissue reinforcement technology developer a contract from its group purchasing organization Premier Purchasing Partners L.P. and a dual-source surgical mesh agreement for Premier’s Accelerated Supply Chain Endeavor program participants. Premier’s network of more than 2,300 U.S.-based hospitals and over 68,000 health centers band together to negotiate contracts with medical product companies.